All articles tagged with #peptides
Blockchain data show U.S. peptide buyers are funneling crypto payments to China-based fentanyl-precursor suppliers, as the peptide market surges in popularity. Regulators, including an FDA advisory panel considering peptides for compounding, may reshape how these products are regulated, raising safety and supply-chain concerns for buyers who may not know who provides their substances.
Doctors warn that Melanotan II, an unregulated peptide marketed to boost tanning, can cause changes in moles and potentially skin cancer; case reports link it to melanoma and mole growth, with injections and no proven medical benefit, so experts advise avoiding gray-market peptides for tanning.
A wellness-driven surge in peptide injections touted for healing, recovery, and muscle-building rests on limited clinical evidence and carries safety risks. In 2023 the FDA banned production of several peptides by compounding pharmacies due to safety concerns and impurities, and the agency does not approve such compounds. US policy discussions about legalizing broader compounding could boost access but also risk, as product quality and dosing vary and most data come from animal studies. Experts urge caution and emphasize that rigorous human trials are still needed to establish true benefits and safety.
Dermatologists say certain peptides can support the hair growth cycle by improving scalp health and blood flow; The Ordinary's multi-peptide serum—fragrance- and sulfate-free, easy to use, and under $25—has strong user reviews for reducing shedding and encouraging new growth, though experts caution it's complementary rather than a miracle and works best with treatments like PRP for more advanced hair loss.
FDA scientists say seven peptides being considered for compounding pharmacies lack sufficient human data and may pose safety risks, challenging RFK Jr.'s push to deregulate them; an FDA advisory committee will review the evidence July 23–24, but several peptides have little or no human research, raise concerns about contamination and mislabeling, and the FDA must decide, usually following the panel.
Kennedy has packed the FDA’s Pharmacy Compounding Advisory Committee with peptide advocates and industry ties, even as FDA scientists warn that several popular injectable peptides lack proven safety or efficacy. The agency added nine new members (raising the panel to 13) who will review seven peptides and consider whether compounding pharmacies can produce them for human use, with final determinations expected after input from the advisory process.
The FDA disclosed eight new panelists for a peptide regulation panel, many tied to peptide-related businesses, prompting concerns that regulatory outcomes could favor industry over public health.
Peptides have surged in popularity as unregulated wellness ‘cures,’ but human evidence remains thin: animal studies show promise for obesity, aging and tissue repair, yet controlled human data are scarce; many products are sold as ‘research use only’ with variable purity, and FDA moves to ease access could slow evidence generation and raise safety concerns.
A growing number of teens are injecting black-market peptides they find on social media—such as retatrutide and melanotan—for quick weight loss and tanning. Sourced through informal networks like Telegram, these products are often labeled “not for human consumption” and used in DIY stacks, with minimal medical oversight and unknown long-term health risks. Experts warn that adolescence is a critical development period, and unregulated, rapidly acting peptides can have serious consequences, including hormonal disruption, cardiovascular issues, and skewed body image driven by looksmaxxing culture.
Retatrutide is an experimental peptide that targets GLP-1, GIP, and glucagon to suppress appetite and boost fat loss; it’s unapproved globally and already circulating online, with early trials showing strong weight loss but under strict medical supervision. Real‑world use carries safety concerns like gastrointestinal side effects and at least one death being investigated; lack of regulation means contaminated or misdosed products are possible, and Australia’s TGA has warned about importing unapproved peptides. Experts caution that achieving shredded results depends on resistance training and protein intake, and mood or relationship effects are still unclear.
FDA plans advisory panels to reconsider compounded peptides; a sweeping Cochrane review revives debates over amyloid-targeting Alzheimer’s drugs; Roche will run another Elevidys trial outside the U.S. as Sarepta markets it domestically; Lilly’s Foundayo GLP-1 pill shows non-inferiority to insulin glargine with a FDA submission planned by the end of Q2.
The FDA announced July 2026 and February 2027 advisory meetings to consider restoring access to 12 unproven peptides previously removed from a compounding-drug list due to safety risks, despite no new supporting safety or efficacy data. RFK Jr. has championed these peptides, claiming the meetings will “restore science,” while critics warn the Pharmacy Compounding Advisory Committee is under-staffed and at risk of being populated by allies, potentially circumventing standard drug-approval scrutiny. The seven peptides to be reviewed in July are BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, and Epitalon; the five scheduled for February 2027 are Cathelicidin LL-37, GHK-Cu, Dihexa-acetate, Melanotan II, and Mechano Growth Factor PEG-MGF, all of which lack proven uses.
Hims & Hers Health is pursuing peptides as a potential growth driver as its high‑margin compounded GLP‑1 business matures. The FDA plans a July 2026 review of peptides for possible inclusion on the 503A bulk list, a step that could enable regulated, physician‑led peptide therapy and unlock new revenue, though progress is not immediate and clinical evidence is limited. The company bought a peptide facility in 2025 and intends to steer users toward branded therapies rather than proprietary compounded GLP‑1 drugs.
Hims & Hers Health shares jumped about 13% in regular trading after RFK Jr. suggested the FDA may ease restrictions on peptide therapies, lifting sentiment for the healthcare/biotech sector.
The FDA says it will convene a July advisory panel to decide whether seven popular but unproven peptide injections should be added to a list allowing pharmaceutical compounding, potentially easing restrictions. The move aligns with Health Secretary RFK Jr.’s push to loosen peptide regulations and the stance of MAHA supporters, though critics warn that most peptides lack safety data and could bypass traditional drug testing. Even if advisers approve, the agency must still complete formal rulemaking. Some peptides are banned by sports bodies and have previously been placed on restricted lists due to health risks, underscoring ongoing safety concerns around this market.